Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | TK2 | O00142 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16373946 | 0.86 | TK1 (0.52) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL933426 | 0.86 | TK1 (0.55) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL19876156 | 0.86 | TK1 (0.52) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL22015702 | 0.86 | TK1 (0.52) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL12736937 | 0.86 | TK1 (0.52) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL16363404 | 0.86 | TK1 (0.52) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL24420691 | 0.85 | TK1 (0.59) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL27060411 | 0.85 | TK1 (0.59) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL27054129 | 0.85 | TK1 (0.59) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL21051291 | 0.84 | TK1 (0.52) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116437973-A | Method for preparing high-function artificial organ by using aptamer | 康干细胞生物科技有限公司 | 2023-07-14 | — | — | CN | disclosed |
| CN-114072504-A | Aptamer specifically binding to cancer stem cells and use thereof | 株式会社海赛尔科技 | 2022-02-18 | — | — | CN | disclosed |
| CN-112807427-A | Use of an anti-CXCL 10 antibody for the preparation of a medicament for treating an inflammatory disease in a subject | 吉安特科技公司 | 2021-05-18 | — | — | CN | disclosed |
| US-20200157543-A1 | BIOMOLECULE IMAGING METHOD USING APTAMER | INTEROLIGO CORPORATION (KR) | 2020-05-21 | — | — | US | disclosed |
| EP-3636287-A1 | BIOMOLECULE IMAGING METHOD USING APTAMER | Interoligo Corporation (KR) | 2020-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157543-A1 | BIOMOLECULE IMAGING METHOD USING APTAMER | ERBB2, ERBB3, ERBB4 | TK1 9/4885LMNA 2535/4885SMN1; SMN2 2448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.